echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sword refers to fibrosis this heavy field! Beijing Ted Pharmaceuticals a class of innovative drugs declared the U.S. FDA.

    Sword refers to fibrosis this heavy field! Beijing Ted Pharmaceuticals a class of innovative drugs declared the U.S. FDA.

    • Last Update: 2020-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    TDI01 can be treated in all aspects of fibrosis development by inhibiting ROCK2 and at the same time inhibiting fibrosis, anti-inflammatory and immunomodulation.
    research data was highly recognized by Professor Scott L. Friedman, Director of the Hepatology Center at Mount Sinai Hospital in the United States, and Professor Dai Huaping, Director of Respiratory and Critical Illness at Sino-Japanese Friendship Hospital.
    , at the same time, a joint study of pulmonary fibrosis markers is being conducted with Professor Ding sen, Distinguished Professor of the Second Hospital of Huaxi And The National Key Laboratory for Biological Therapy, and Professor Charles A Powell, Director of Respiratory Medicine at Mount Sinai Hospital in the United States.
    at present, the global lack of effective drugs to treat fibrosis, non-alcoholic fatty hepatitis caused by hepatic fibrosis in the world has not been approved varieties, a variety of interstitial pulmonary disease caused by pulmonary fibrosis treatment methods are also very limited. TDI01, a new target developed by
    Ted Pharmaceuticals, will provide new treatment options in this critical clinical area.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.